Switzerland / Netherlands / Belgium / Japan / United States / Denmark / / /
Event
FDA Phase / /
Facility
Institute of Bioscience / Institute of Biotechnology / Dartmouth College / GlcNAc β-1 / 4-Man α-1 / 6-Man α-1 / 2-Man GlcNAc2Man3 α-1 / 3-Man GalT Complex / Ghent University / /
IndustryTerm
yeast-based manufacturing / recombinant product / improved biopharmaceutical expression / manufacturing strategy / lower eukaryotic expression systems / biotechnology / genetic tools / protein expression systems / enzymatic processing / yeast systems / treatment of Gaucher’s disease / posttranslational processing / preclinical manufacturing / in vitro processing / final product / fungal protein expression systems / post-translational processing / fungal expression systems / treatment of Gaucher disease / chemical entities / manufacturing / chemical means / attractive solution / /
MedicalCondition
Infanrix-Penta Hepatitis B / human Ambirix Hepatitis B / Comvax Hepatitis B / glycan intermeProcomvax Hepatitis B / yeast glycosylation Elastase inhibitor Cystic fibrosis Dyax P. pastoris / mammalian glycosylation albumin burns/shock / Twinrix Hepatitis B / HBVAXPRO Hepatitis B / conPediarix Hepatitis B / Gaucher disease / Gaucher’s disease / Hexavac Hepatitis B / Kallikrein inhibitor Hereditary / anemia / /
Organization
Institute of Bioscience / Institute of Biotechnology / S. Assembly / Ghent University / Department of Biological Sciences / Thayer School of Engineering / Dartmouth College / Department of Chemistry / Institute of Bioscience and Human Technology / European Union / /
Person
Nat / Berna Biotech / /
Position
engineer / reporter / /
Product
Novolog / Leukine / Glucagon / Humulin / United States / /
ProgrammingLanguage
php / /
ProvinceOrState
New York / South Carolina / Iowa / New Hampshire / /
© 2004 Nature Publishing Group http://www.nature.com/naturebiotechnology REVIEW Advances in the production of human therapeutic proteins in yeasts and